

Remarks

Upon entry of the above amendments, this application will contain claims 1-5, 8, 9, 12, 14, 16, 18, 20, 22, and 26 pending and under consideration. In the present Response no claims have been canceled or added. Claims 1, 3, 5, 8, 16, and 20 have been amended. As discussed more fully below, it is believed that this application is in condition for allowance. Reconsideration leading to withdrawal of all rejections and objections is requested.

I. It was acknowledged in the latest Office Action that all previous rejections under 35 USC §112, first paragraph were withdrawn. (Office Action, page 2.)

II. It was also acknowledged in the latest Office Action that all previous rejections under 35 USC §112, second paragraph were withdrawn except for the rejection of claim 5. (See Office Action dated 16 April 2009, paragraph 3i.)

Claim 5 has been amended to correct the minor typographical error where “C₁-C₆ alkycycloalkyl” has been replaced with --C₁-C₆ alkylcycloalkyl--. (Italics added.) In light of the amendment, withdrawal of this rejection is requested.

III. Objections to Claims 1, 3, 5, and 20.

Objections were raised to claim 1, 3, 5 and 20 for variety of missing spaces, commas and other minor typographical errors. In response the following amendments are presented.

In claim 1, on line 7¹, a space is added after “heterocycll”; on line 8 a space was deleted after “-NR⁷R⁸;”; on line 9 a space was after “-OC₁-C₆ alkylheterocyclic”; on line 11 a common was removed after CONR¹¹R¹², and a space was added after C₀-C₃ alkylNR¹¹R¹². on line 16 a comma was deleted after “oxo”; on line 14 a space was deleted after “from”; and on line 12 a comma and a space was deleted after the word “aryl”.

In claim 3, on line 5 a comma was removed after the period.

In claim 5, on line 1 a comma was added after the words “to Claim 1”; on line 2, “C₁-C₆ alkycycloalkyl” was replaced with --C₁-C₆ alkylcycloalkyl--.

In claim 8, on line 1 a space was added after “q is”.

In claim 16, on line 2 the word --or--was added after the words “claim 1”.

¹ The line numbers were determined without consideration or counting any lines for the structure(s) in the claims.

In claim 20, on line 3 a comma and a space were added after “claim 1” and a comma was deleted after the word “salt”.

Withdrawal of the objections to claims 1, 3, 5, and 20 is requested.

In addition, objections were raised for claims 2, 4, 8, 9, 14, 16, 18, 22, and 26 for being dependent upon an objected base claim. In light of the above amendments withdrawal of this objection is requested.

A clean copy of the amended claim set is appended to this response for the Examiner’s convenience.

IV. Conclusion

In light of the above claim amendments and comments withdrawal of all rejections and objections is requested. Applicants respectfully request timely reconsideration examination of this application leading to allowance of all elected claims. The Examiner is invited to contact the undersigned attorney by telephone if there are any questions, further objections, or other issues that may be addressed in that fashion.

Respectfully submitted,

/James B. Myers/
James B. Myers
Attorney for Applicants
Registration No. 42,021
Phone: 317-276-0755

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
February 10, 2010